["{\n\"step_by_step_thinking\": \"The question is about Nivolumab (Opdivo) being a PD-L1 inhibitor. Since none of the provided documents discuss pharmaceuticals or immune checkpoint inhibitors, we can conclude that there is no direct information about Opdivo's mechanism of action in these texts.\",\n\"answer_choice\": \"B: no\"\n}"]